Avicanna Stock (OTC:AVCNF), Trade Ideas

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

emilio-takas-_GNVwZJv-Jo-unsplash(1)

Cannabis

Earnings

News

AVCNF

TSX:AVCN

Cannabinoids-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) reported on Tuesday year-end 2023 results and audited financial statements. The Canadian company reported CA$16.8 million ($12.3 million) in total revenue, up by 314% year-over-year. Avicanna mostly attributed a surge in revenue to the acquisition of Medical Cannabis by Shoppers from Shoppers Drug Mart and the launch of MyMedi.ca. &#34;2023 was a tremendous year for Avicanna where we solidified our leadership position in the Canadian medical cannabis sector through our proprietary products and the launch of MyMedi.ca,&#34; he said. &#34;We have successfully demonstrated the scalability of our revenues and made significant improvements in our fundamentals while advancing all our business pillars.&#34;

Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY

national-cancer-institute-cQ8FfVNvbew-unsplash

Entrepreneurship

Health Care

TLRY

MMJ.com, a telehealth platform providing access to medical marijuana, has expanded its services to 26 states. This expansion allows patients to consult state-certified doctors online for medical cannabis treatment, enhancing patient access and promoting the potential benefits of medical marijuana as an alternative therapy. The move also reflects the evolving legal and regulatory landscape surrounding cannabis, indicating changing perspectives at the state and federal levels. MMJ.com&#39;s use of telehealth for patient-doctor connectivity highlights a trend toward innovative healthcare solutions, especially in specialized care areas. Other companies like Tilray Medical, Avicanna Inc., and Tyler Technologies are also working to destigmatize cannabis through education platforms and licensing solutions, further promoting the understanding and acceptance of medical cannabis for patients and healthcare practitioners.

This Company Is Bringing Medical Marijuana Telehealth To Over Half The U.S.

AI generated image

Biotech

Penny Stocks

Markets

General

CLVR

CLVRW

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

PCLOF

Can Cannabis Treat Severe Forms Of Epilepsy? New Medicine Sparks Hope As Colombia&#39;s Weed Industry Goes Global

Avicanna Inc

<p>Financial giants have made a conspicuous bullish move on Trade Desk. Our analysis of options history for Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) revealed 14 unusual trades.</p>
<p>Delving into the details, we found 78% of traders were bullish, while 21% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $820,467, and 7 were calls, valued at $516,755.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $140.0 for Trade Desk during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Trade Desk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Trade Desk's substantial trades, within a strike price spectrum from $80.0 to $140.0 over the preceding 30 days.</p>
<h3>Trade Desk Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463463_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$7.65</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$82.50</td>
<td>$594.3K</td>
<td>1.9K</td>
<td style="text-align: right;">796</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$6.8</td>
<td>$6.75</td>
<td>$6.8</td>
<td>$82.50</td>
<td>$136.0K</td>
<td>1.0K</td>
<td style="text-align: right;">710</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$6.75</td>
<td>$6.7</td>
<td>$6.75</td>
<td>$82.50</td>
<td>$135.0K</td>
<td>1.0K</td>
<td style="text-align: right;">110</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$6.75</td>
<td>$6.7</td>
<td>$6.75</td>
<td>$82.50</td>
<td>$73.5K</td>
<td>1.0K</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$49.1</td>
<td>$48.85</td>
<td>$49.1</td>
<td>$130.00</td>
<td>$54.0K</td>
<td>1</td>
<td style="text-align: right;">22</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<p>Having examined the options trading patterns of Trade Desk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Trade Desk</h3>
<ul>
<li>Trading volume stands at 895,488, with TTD's price up by 0.7%, positioned at $80.69.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
<h3>What The Experts Say On Trade Desk</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $100.0.</p>
<ul>
<li>An analyst from Needham downgraded its action to Buy with a price target of $100. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Trade Desk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Trade Desk's Options Frenzy: What You Need to Know

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Toll Brothers</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TOL, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Toll Brothers.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.</p>
<p>Out of all of the options we uncovered, 8 are puts, for a total amount of $451,815, and there was 1 call, for a total amount of $63,750.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $120.0 for Toll Brothers, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Toll Brothers stands at 405.5, with a total volume reaching 1,900.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Toll Brothers, situated within the strike price corridor from $100.0 to $120.0, throughout the last 30 days.</p>
<h3>Toll Brothers Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463457_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$10.2</td>
<td>$9.9</td>
<td>$9.9</td>
<td>$120.00</td>
<td>$76.4K</td>
<td style="text-align: right;">250</td>
<td style="text-align: right;">713</td>
</tr>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$10.2</td>
<td>$9.9</td>
<td>$9.9</td>
<td>$120.00</td>
<td>$76.3K</td>
<td style="text-align: right;">250</td>
<td style="text-align: right;">713</td>
</tr>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$9.7</td>
<td>$9.4</td>
<td>$9.55</td>
<td>$120.00</td>
<td>$69.9K</td>
<td style="text-align: right;">250</td>
<td style="text-align: right;">214</td>
</tr>
<tr>
<td>TOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$25.8</td>
<td>$25.3</td>
<td>$25.5</td>
<td>$100.00</td>
<td>$63.7K</td>
<td style="text-align: right;">561</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$9.5</td>
<td>$9.1</td>
<td>$9.35</td>
<td>$120.00</td>
<td>$56.1K</td>
<td style="text-align: right;">250</td>
<td style="text-align: right;">60</td>
</tr>
</tbody>
</table>
</p>
<h3>About Toll Brothers</h3>
<p>Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-home buyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the U.S. It has its headquarters in Horsham, Pennsylvania.</p>
<p>Following our analysis of the options activities associated with Toll Brothers, we pivot to a closer look at the company's own performance.</p>
<h3>Toll Brothers's Current Market Status</h3>
<ul>
<li>Trading volume stands at 573,889, with TOL's price up by 0.08%, positioned at $113.51.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 33 days.</li>
</ul>
<h3>What Analysts Are Saying About Toll Brothers</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $147.5.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Toll Brothers with a target price of $157. </li>
<li>Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Toll Brothers, targeting a price of $138. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Toll Brothers options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Decoding Toll Brothers's Options Activity: What's the Big Picture?

<p>Financial giants have made a conspicuous bearish move on B. Riley Financial. Our analysis of options history for B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 11% of traders were bullish, while 88% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $267,455, and 2 were calls, valued at $60,017.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $25.0 for B. Riley Financial over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in B. Riley Financial's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to B. Riley Financial's substantial trades, within a strike price spectrum from $20.0 to $25.0 over the preceding 30 days.</p>
<h3>B. Riley Financial 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463451_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RILY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$3.5</td>
<td>$3.2</td>
<td>$3.31</td>
<td>$20.00</td>
<td>$76.1K</td>
<td>3.1K</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>RILY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$1.65</td>
<td>$1.45</td>
<td>$1.65</td>
<td>$21.00</td>
<td>$37.2K</td>
<td>140</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>RILY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$1.7</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$21.00</td>
<td>$35.2K</td>
<td>140</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>RILY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$3.4</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$20.00</td>
<td>$32.0K</td>
<td>762</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>RILY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$2.9</td>
<td>$2.4</td>
<td>$2.45</td>
<td>$22.00</td>
<td>$31.3K</td>
<td>383</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About B. Riley Financial</h3>
<p>B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional and high net worth clients and also asset disposition, valuation and appraisal and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer segment.</p>
<p>In light of the recent options history for B. Riley Financial, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of B. Riley Financial</h3>
<ul>
<li>Trading volume stands at 192,897, with RILY's price down by 0.0%, positioned at $20.46.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for B. Riley Financial with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


RILY

Check Out What Whales Are Doing With RILY

<p>Needham  analyst Kyle Peterson   reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $305 price target.</p>


Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Equifax, Maintains $305 Price Target

<p>In the last three months, 5 analysts have published ratings on IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for IGM Biosciences, presenting an average target of $17.2, a high estimate of $21.00, and a low estimate of $12.00. Observing a 115.0% increase, the current average has risen from the previous average price target of $8.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463344_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive IGM Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Driscoll</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IGM Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of IGM Biosciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of IGM Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into IGM Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IGMS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on IGM Biosciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into IGM Biosciences's Background</h2>
<p>IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.</p>
<h3>Financial Milestones: IGM Biosciences's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> IGM Biosciences's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>75.0%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> IGM Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-9323.35%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> IGM Biosciences's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-26.56%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> IGM Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-13.52%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> IGM Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.2</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IGMS

What 5 Analyst Ratings Have To Say About IGM Biosciences

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) in the last three months.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.14, along with a high estimate of $13.00 and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 6.68% increase from the previous average price target of $11.38.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463317_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Rithm Capital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trevor Cranston</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Erdner</td>
<td>JonesTrading</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Matt Howlett</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Rithm Capital. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rithm Capital compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Rithm Capital's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Rithm Capital's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RITM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rithm Capital analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Rithm Capital</h2>
<p>Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company's mission is to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Rithm Capital's investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans.</p>
<h3>Breaking Down Rithm Capital's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Rithm Capital's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-21.17%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Rithm Capital's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-26.07%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Rithm Capital's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-1.5%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Rithm Capital's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.25%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Rithm Capital's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>4.19</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RITM

Expert Ratings For Rithm Capital

<p>Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $38.2, along with a high estimate of $51.00 and a low estimate of $24.00. This current average has increased by 48.35% from the previous average price target of $25.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463287_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Dianthus Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Seedhouse</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Maury Raycroft</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Alex Thompson</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dianthus Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Dianthus Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Dianthus Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DNTH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dianthus Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Dianthus Therapeutics: A Closer Look</h2>
<p>Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.</p>
<h3>Dianthus Therapeutics: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Dianthus Therapeutics faced challenges, resulting in a decline of approximately <strong>-61.11%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Dianthus Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-2311.38%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dianthus Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-6.08%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Dianthus Therapeutics's ROA excels beyond industry benchmarks, reaching <strong>-5.68%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Dianthus Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.0</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DNTH

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics

<p>Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) has outperformed the market over the past 15 years by 8.83% on an annualized basis producing an average annual return of 21.22%. Currently, Adobe has a market capitalization of $212.35 billion. </p>
<p><strong>Buying $1000 In ADBE:</strong> If an investor had bought $1000 of ADBE stock 15 years ago, it would be worth <strong>$19,362.34</strong> today based on a price of $473.99 for ADBE at the time of writing.</p>
<h3>Adobe's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463281_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

ADBE

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $19,000 Today

<p>Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) has outperformed the market over the past 20 years by 3.68% on an annualized basis producing an average annual return of 11.34%. Currently, Lowe's Companies has a market capitalization of $130.60 billion. </p>
<p><strong>Buying $1000 In LOW:</strong> If an investor had bought $1000 of LOW stock 20 years ago, it would be worth <strong>$8,566.34</strong> today based on a price of $228.25 for LOW at the time of writing.</p>
<h3>Lowe's Companies's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463275_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Lowe's Companies 20 Years Ago Would Be Worth This Much Today

<p>Providing a diverse range of perspectives from bullish to bearish, 17 analysts have published ratings on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Merck &amp; Co, presenting an average target of $135.35, a high estimate of $148.00, and a low estimate of $104.00. This upward trend is apparent, with the current average reflecting a 2.54% increase from the previous average price target of $132.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463271_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Merck &amp; Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Luisa Hector</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$143.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Justin Smith</td>
<td>Societe Generale</td>
<td>Announces</td>
<td>Sell</td>
<td>$104.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Merck &amp; Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merck &amp; Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Merck &amp; Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Merck &amp; Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MRK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Merck &amp; Co analyst ratings.</strong></a></p>
<h2>Discovering Merck &amp; Co: A Closer Look</h2>
<p>Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.</p>
<h3>Merck &amp; Co: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Merck &amp; Co's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>5.78%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Merck &amp; Co's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-8.38%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Merck &amp; Co's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-3.11%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Merck &amp; Co's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-1.15%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.93</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 17 Analyst Insights On Merck & Co

<p>Bio-Path Holdings, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) (the "Company" or "Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize&#xAE; antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants to purchase up to 375,000 shares of common stock at an exercise price of $3.10 per share. The unregistered warrants to be issued in the private placement will become immediately exercisable upon issuance and will expire five years from the date of issuance. The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.<br /><br />&nbsp;</p>
<p>Immediately prior to the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company was 1,190,306. Immediately following the closing of the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company will be 1,565,306.</p>
<p>H.C. Wainwright &amp; Co., LLC is acting as the exclusive placement agent for the offering.</p>


Offerings

BPTH

Bio-Path Holdings Announces $1.2M Registered Direct Offering With Some Institutional Investors For Sale Of 375,000 Shares Of Its Common Stock At Price Of $3.225/Share

<p>In the latest quarter, 9 analysts provided ratings for Clear Secure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.22, along with a high estimate of $40.00 and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 23.58% increase from the previous average price target of $28.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463232_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Clear Secure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Clear Secure. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Clear Secure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Clear Secure's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Clear Secure's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/YOU/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Clear Secure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Clear Secure Better</h2>
<p>Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in the creation of a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports which helps to make the travel experience safe and easy.</p>
<h3>Clear Secure: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Clear Secure's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>33.3%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Clear Secure's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.17%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Clear Secure's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.49%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.33%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Clear Secure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.55</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Clear Secure Through The Eyes Of 9 Analysts

<p>In the preceding three months, 6 analysts have released ratings for S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for S&amp;P Global, presenting an average target of $487.5, a high estimate of $520.00, and a low estimate of $442.00. This current average has increased by 1.56% from the previous average price target of $480.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713463217_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive S&amp;P Global is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$442.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$520.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$480.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$483.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>-</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to S&amp;P Global. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of S&amp;P Global compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for S&amp;P Global's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into S&amp;P Global's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SPGI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on S&amp;P Global analyst ratings.</strong></a></p>
<h2>Delving into S&amp;P Global's Background</h2>
<p>S&amp;P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&amp;P's largest segment by profitability. S&amp;P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&amp;P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.</p>
<h3>Financial Milestones: S&amp;P Global's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, S&amp;P Global showcased positive performance, achieving a revenue growth rate of <strong>7.32%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> S&amp;P Global's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>18.37%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.66%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> S&amp;P Global's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.96%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> S&amp;P Global's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.35</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SPGI

Expert Ratings For S&P Global

<p>Consumers are spending more money monthly on video streaming plans. But, as consumers look to cut streaming plans as costs go up, only the best and most-loved platforms will thrive, which could be bad news <a href="https://www.benzinga.com/topic/streaming-stocks" target="_blank" rel="noreferrer noopener">for streaming stocks.</a></p>
<p><strong>What Happened</strong>: Benzinga recently polled its website readers to ask which streaming platform would be the one they would keep if they were forced to choose. </p>
<p>The poll came ahead of highly anticipated<a href="https://www.benzinga.com/news/earnings/24/01/36747282/netflix-q4-earnings-highlights-revenue-beat-13-12-million-net-paid-subscribers-q1-guidance-and-more"> first-quarter earnings</a> from streaming leader<strong> Netflix Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).</p>
<p><strong>The question was: "If you could keep one of the following streaming platforms, which would you choose?"</strong></p>
<p>The results were as follows:</p>
<p><strong>Disney+</strong>: 8%</p>
<p><strong>Netflix:</strong> 61%</p>
<p><strong>Amazon Prime Video</strong>: 24%</p>
<p><strong>MAX:</strong> 7%</p>
<p>The results of the poll showed the dominance of Netflix with the streaming platform picked by more than 60% of respondents as the one to keep.</p>
<p>Netflix spent aggressively on acquired and original content over the year and continues to have some of the most streamed shows and movies. Its shows also trend as topics worldwide.</p>
<p>Ranking second in the poll was Amazon Prime Video, which is owned by <strong>Amazon.com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). Amazon acquired MGM in a move that significantly boosted its library of content. The company has also been aggressive in acquiring sports rights, including being the exclusive home of "Thursday Night Football."</p>
<p>A study recently showed Prime Video had<a href="https://www.benzinga.com/general/entertainment/24/04/38024244/appletv-a-streaming-winner-new-survey-shows-platform-has-smallest-library-highest-rated-con"> the largest library</a> of shows and movies, ranking ahead of Netflix.</p>
<p>Disney+ from<strong> Walt Disney Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) and MAX from <strong>Warner Bros. Discovery</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) ranked third and fourth, respectively.</p>
<p>Content on Disney+ appeals to fans of some of the biggest franchises of all time including Star Wars and Marvel. The platform also has a vast library of kids' content, which could make it a must-have for families.</p>
<p>Max is the home of content from HBO and offers content from brands like Discovery Channel, CNN, Cartoon Network, Adult Swim and Animal Planet. The platform has sports content too, which might appeal to certain streaming users. Max comes in on the pricier side of the streaming platforms, which could have impacted the poll results.</p>
<p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38278466/netflix-q1-earnings-preview-subscriber-growth-potential-price-increase-ad-tier-plan">Netflix Q1 Earnings Preview: Subscriber Growth, Potential Price Increase, Ad-Tier Plan And More On What Wall Street Expects</a></em></p>
<p><strong>Why It's Important</strong>: A recent Deloitte survey showed that U.S. consumers<a href="https://www.benzinga.com/general/entertainment/24/03/37871210/us-consumers-pay-average-61-month-for-streaming-services-and-theyre-not-going-to-pay-for-ra"> spend $61 per month</a> on streaming platforms.</p>
<p>In the survey, 36% said that the content was not worth the money for most platforms.</p>
<p>An alarming statistic for the streaming sector was that 40% of households said they had canceled at least one streaming service in the past six months. Forty-eight percent of respondents said they would cancel a streaming platform if the price went up $5 or more monthly.</p>
<p>Netflix reports first-quarter financial results Thursday, April 18 and among the key items investors and analysts are watching is a potential price hike for its ad-free plans.</p>
<p><em>The study was conducted by Benzinga from April 16, 2024 to April 18, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 397 adults.</em></p>
<p><em>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38228178/netflix-q1-subscriber-estimates-too-high-analyst-cautions-on-elevated-expectations-">Netflix Q1 Subscriber Estimates Too High? Analyst Cautions On Elevated Expectations, &#8216;How Big Is The Beat&#8217; Mentality</a></em></p>
<p><em>Photo: <a href="https://www.shutterstock.com/g/proximastudio">Proxima Studio</a> via Shutterstock</em></p>


Entertainment

Exclusives

Media

AMZN

NFLX

EXCLUSIVE: Streaming Platform Winner Picked By Benzinga Readers: Did Disney+, Netflix, Amazon Prime Video Or Max Take Top Honors?

<p>HC Wainwright &amp; Co.  analyst Edward White   reiterates TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Buy and maintains $45 price target.</p>


TGTX

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $45 Price Target

<p><strong>Senator Jacky Rosen</strong> (D-NV) introduced legislation on Thursday aimed at establishing a cannabis-related federal grant program that would automatically fund expunging or sealing cannabis-related records at the state level, leveraging federal resources. </p>
<p>The <strong>Harnessing Opportunity by Pursuing Expungement,</strong> or HOPE Act was initially introduced by a bipartisan group of House members in two straight Congresses <a href="https://www.benzinga.com/markets/cannabis/23/04/31870371/aoc-and-ohio-rep-dave-joyce-refile-hope-act-to-assist-state-level-marijuana-expungements">led by <strong>Rep. Alexandria Ocasio-Cortez </strong>(D-NY) and <strong>Rep.</strong> <strong>Dave Joyce</strong></a> (R-OH). </p>
<p>Introducing it now in the Senate, Rosen seeks the support of Senate Majority Leader Chuck Schumer (D-NY), <a href="https://thenevadaindependent.com/article/rosen-introduces-bill-to-federally-fund-automatic-cannabis-record-sealing-at-state-level">reported</a> The Nevada Independent. Rosen&#8217;s aim is for the bill to be included in an anticipated cannabis reform package, focusing on banking reforms that Congress and industry leaders are advocating for this month, coinciding with the marijuana holiday, 4/20.</p>
<p>The disproportionate impact of cannabis-related imprisonment on minority groups, particularly Black Americans, has been a significant concern. Statistics show that Black individuals are three times more likely to be arrested for cannabis offenses than their white counterparts though there are no significant statistical differences in substance use between groups. </p>
<p>This disparity motivated Rosen, a <a href="https://www.benzinga.com/markets/cannabis/24/02/37211690/sen-jacky-rosen-releases-video-calling-for-federal-marijuana-legalization-pushes-fda-to-reschedu">longstanding advocate for cannabis reform</a>, to join forces with Reps. Ocasio-Cortez and Joyce in their goal to provide relief for communities most affected by prohibition and still bearing the brunt in this post-prohibition era.</p>
<h3 class="wp-block-heading">The Burden Of Being Unjustly Sentenced</h3>
<p>The administrative expenses associated with clearing criminal offense records are substantial. Given that these charges predominantly affect minority communities with fewer resources and who have been doubly impacted by both racial and economic segregation and cannabis prosecution, subsidizing their costs and erasing these fees is critical. </p>
<p>Should it be enacted, the new State Expungement Opportunity Grant Program would fall under the administration of the Justice Department. The program&#8217;s objective is to reduce the administrative burden associated with pinpointing and expunging eligible cases.</p>
<h3 class="wp-block-heading">Past Offenders And Cannabis</h3>
<p>The debate around cannabis has centered on fighting prohibition at every turn. While the potential for economic freedom and tax revenue has been persuasive, some core arguments for legalization lie in social justice and equal opportunities.</p>
<p>There have been two primary approaches to addressing the plight of past offenders. One involves erasing records and repairing the damages caused by the unjust prosecution of cannabis users. This approach underpins the rationale for cannabis pardons and record clearing. The other strategy involves integrating those affected into <a href="https://www.benzinga.com/events/cannabis-conference/social-equity-initiatives/">social equity </a>programs, helping them alleviate capital requirements to participate in the industry.</p>
<p>Past offenders continue to suffer under the shadow of outdated marijuana laws. They face significant barriers to employment and housing due to their convictions. This initiative represents a step toward rectifying those injustices, offering hope and tangible support to those seeking to rebuild their lives. Erasing marijuana offenses from records is essential for enabling those impacted to move forward with their lives with less burden. This is the objective Rosen and her colleagues say they are striving to achieve.</p>


Government

Regulations

Sen. Jacky Rosen Introduces Bill Seeking Fed Grants To Cover Expungement Costs For People Unjustly Sentenced For Cannabis Offenses

<p>BioNexus Gene Lab Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC's commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics.</p>
<p><strong>Background:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>●</td>
<td><strong>MRNA Scientific Sdn Bhd</strong>:</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>○&nbsp;</td>
<td>
<p>A wholly-owned subsidiary of BGLC, MRNA Scientific specializes in blood-based genomic screening and dynamic genome profiling.</p>
<p>MRNA's innovative techniques enable early disease detection, personalized health management, and AI-driven insights.</p>
</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>●&nbsp;</td>
<td><strong>Ascension Innovation Sdn Bhd (AISB)</strong>:</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>○</td>
<td>AISB is a trailblazer in healthcare technology, committed to enhancing patient experiences and outcomes.</td>
</tr>
<tr>
<td>○</td>
<td>Their flagship platform, aiCMS, empowers clinics, physicians, and patients to have better control over healthcare delivery through personalized patient health management.</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><strong>Strategic Investment and Handover Ceremony:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td>MRNA Scientific's investment of <strong>RM 1.2 million (approx. USD $250k)</strong> will occur in two tranches. The Company has made an initial payment of approx. RM 100k, to be followed by a final payment of RM 1.1million, subject to a formal agreement. Our investment in AISB signifies a strategic move to accelerate healthcare innovation. The investment, funded internally, is expected to constitute an indicative equity of approximately 10% of the ordinary shares in AISB upon completion.</td>
</tr>
<tr>
<td>·</td>
<td>The infusion of capital will further AISB's development and accelerate its AI rollout, including:</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>o</td>
<td><strong>AI Assistance in the Clinic and on-App: </strong>The AI features include the integration of predictive and generative AI note taking/analysis and diagnosis aids via Large Language Model (LLM), voice transcription, and natural language assistance for service selection and bookings.</td>
</tr>
<tr>
<td>o</td>
<td><strong>Predictive Analytics and Personalized Solutions</strong>: aiCMS will enhance early disease detection and personalized health recommendations in clinic and on-app, with the integration of in-app predictive health and wellness recommendations, medical translation services, and AI medical image analysis.</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><strong>Ceremony Participants:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td colspan="2"><strong>MRNA Scientific Directors</strong>:</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>o</td>
<td><strong>Mr. Kenny Lai</strong></td>
</tr>
<tr>
<td>o</td>
<td><strong>Mr. CC Wong</strong></td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td colspan="2"><strong>AISB Directors</strong>:</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>o</td>
<td><strong>Mr. Andrew Teng (Chief Executive Officer, CEO)</strong></td>
</tr>
<tr>
<td>o</td>
<td><strong>Mrs. Penny Attenbrough (Chief Strategy Officer, CSO)</strong></td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><strong>Expanding Market Reach:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td>MRNA Scientific and BGLC believe that this strategic investment will allow BGLC's Blood-based Genomic Screening (BGS) liquid biopsies and other diagnostic services to be better marketed and accessible to a wider range of customers and healthcare providers, through integration into AISB's aiCMS and the aiCARE app, enabling direct booking via healthcare providers and patients.</td>
</tr>
<tr>
<td>·</td>
<td>By combining MRNA's expertise in genomics and AISB's innovative platform, patients and healthcare professionals will benefit from advanced diagnostics and personalized care.</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><strong>Digital Health &amp; AI Market:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td>The global digital health market size was estimated at <strong>USD 240.9 billion in 2023</strong> and is projected to grow at a compound annual growth rate (CAGR) of <strong>21.9% from 2024 to 2030</strong>1.</td>
</tr>
<tr>
<td>·</td>
<td>The global market size for AI in Healthcare is expected to reach <strong>USD 187.7</strong> billion by 2030 with a compound annual growth rate (CAGR) of <strong>38.5% from 2024 to 2030</strong>2.</td>
</tr>
<tr>
<td>·</td>
<td>Given the market size and opportunities in Digital Health and AI in Healthcare, MRNA and BGLC will closely consider opportunities to increase our participation in this market, including the potential to increase our investment in AISB and other technology platforms.</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><strong>AISB's Projections:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td colspan="2"><strong>Projected Revenue in Malaysia</strong>:</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>o</td>
<td>As stated in its investment documents, AISB anticipates substantial revenue growth driven by increased adoption of aiCMS, with projections reaching RM 75million collectively for 2024-2028.</td>
</tr>
<tr>
<td>o&nbsp;&nbsp;</td>
<td>The platform's comprehensive suite of services positions it as a game-changer in the Malaysian healthcare landscape.</td>
</tr>
<tr>
<td>o</td>
<td>These revenue projections were part of the approved prospectus on the Securities Commission of Malaysia approved pitchIN Funding platform.</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td colspan="2"><strong>Clinics and Service Providers</strong>:</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>o</td>
<td>AISB aims to onboard a significant number of healthcare and wellness providers, and corporations.</td>
</tr>
<tr>
<td>o</td>
<td>Since its recent launch, aiCMS has already proven market traction with over 30 healthcare providers and corporations in its initial segue into this broad market.</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td colspan="2"><strong>User Base and Health Records</strong>:</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>o&nbsp;&nbsp;</td>
<td>With 145,000+ registered users and 340,000+ individual health records in its database, the aiCMS platform is already making an impact in the market.</td>
</tr>
<tr>
<td>o</td>
<td>The platform's scalability has the potential for exponential growth.</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><strong>Quotes:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>·</td>
<td><i>Mr. Sam Tan, CEO, BioNexus Gene Lab Corporation</i>: "Our investment in AISB reflects our belief in their transformative healthcare solutions. Together, we aim to revolutionize patient care through predictive and generative AI."</td>
</tr>
<tr>
<td>·</td>
<td><i>Mr. Andrew Teng, CEO, Ascension Innovation Sdn Bhd</i>: "We welcome MRNA Scientific's support and look forward to leveraging their expertise. The future of healthcare lies in predictive analytics and personalized solutions."</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>The handover ceremony took place at the Apollo Men's Wellness Centre in Starhill, Kuala Lumpur on April 18th, 2024, witnessed by Mr. Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp (BGLC).</p>


Contracts

BGLC

UPDATE: BioNexus Gene Lab Corp. Agrees to Invest $250K In Ascension Innovation (AISB) To Advance Digital Health Innovation Through AI Adoption In Healthcare

<p>U.S. stocks were lower, with the Nasdaq Composite falling over 50 points on Thursday.</p>
<p>Shares of <strong>Ally Financial Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) rose sharply during Thursday's session after the company reported better-than-expected quarterly financial results.</p>
<p>Ally Financial posted adjusted earnings of 45 cents per share, beating market estimates of 33 cents per share. The company's adjusted sales came in at $1.99 billion versus expectations of $1.96 billion.</p>
<p>Ally Financial shares jumped 7.7% to $39.06 on Thursday.</p>
<p>Here are some other big stocks recording losses in today's session.</p>
<ul>
<li><strong>Critical Metals Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) rose 24% to $9.30.</li>
<li><strong>Canopy Growth Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares gained 21.2% to $7.86.</li>
<li><strong>Humacyte, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares rose 13.9% to $3.5550.</li>
<li><strong>Trump Media &amp; Technology Group Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) jumped 13.4% to $29.92. The company in a filing explained to shareholders how to prevent shares from being loaned for a short interest position.</li>
<li><strong>Aquestive Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) jumped 12.4% to $4.4050.</li>
<li><strong>Badger Meter, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) shares jumped 11.8% to $171.06 after the company reported better-than-expected first-quarter results.</li>
<li><strong>FibroBiologics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) rose 11.8% to $10.61.</li>
<li><strong>CleanSpark, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) climbed 11.7% to $16.66 as Bitcoin has gained over the past 24 hours.</li>
<li><strong>Genuine Parts Company</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NASDAQ">GPC</a>) gained 11.1% to $160.05 after the company reported a first-quarter EPS beat and raised its FY24 guidance.</li>
<li><strong>Barnes Group Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>) rose 8.8% to $36.31. DA Davidson analyst Matt Summerville upgraded Barnes from Neutral to Buy and raised the price target from $35 to $45.</li>
<li><strong>Iridium Communications Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) climbed 8.5% to $26.81 after the company reported better-than-expected first-quarter financial results.</li>
<li><strong>Apogee Enterprises, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) surged 8.1% to $60.42 following upbeat quarterly earnings.</li>
<li><strong>ManpowerGroup Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) gained 7.1% to $75.03 following strong second-quarter guidance.</li>
<li><strong>Snap Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) rose 6.2% to $11.58 following recent reports of the TikTok divest-or-ban bill moving on a fast track through Congress.</li>
<li><strong>United Airlines Holdings, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) jumped 4.6% to $50.99 after multiple analysts raised their price targets on the stock.</li>
<li>Now Read This: <a href="https://www.benzinga.com/news/24/04/38316287/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
<p><figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex"><br />
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="612" height="418" data-id="298553" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18140050/Image26-1.jpeg" alt="" class="wp-image-298553" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18140050/Image26-1.jpeg 612w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18140050/Image26-1-300x205.jpeg 300w" sizes="(max-width: 612px) 100vw, 612px" /><figcaption class="wp-element-caption">Double exposure of business woman are trading USA stock market by using digital tablet</figcaption></figure><br />
</figure></p>


Intraday Update

Movers

ALLY

APOG

AQST

CLSK

CRML

FBLG

HUMA

IRDM

SNAP

Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday

<p>Roth MKM  analyst Philip Shen   reiterates Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) with a Buy and maintains $40 price target.</p>


Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $40 Price Target

Boeing Currently Employs 27 R&D Staff From 12 Countries In Japan And Plans To Increase That Number To Around 50 In The Future; Boeing Says Details Of Asia Business Will Be Finalized In Future

Avicanna Non-GAAP EPS of -$0.01, revenue of $6.27M

Avicanna Inc. (AVCNF) Q3 2023 Earnings Call Transcript

Avicanna signs supply and licensing agreement with pharmaceutical company

Avicanna Inc (TSE:AVCN) has released an update. Avicanna Inc., a leader in cannabinoid-based biopharmaceuticals, is set to host an exclusive sympos...

Avicanna Inc. Symposium Explores Medical Cannabis

Avicanna Inc (TSE:AVCN) has released an update. Avicanna Inc., a leader in cannabinoid-based biopharmaceuticals, will discuss its Full Year 2023 fi...

Avicanna Announces Full Year 2023 Earnings Call

Avicanna Inc (TSE:AVCN) has released an update. Avicanna Inc., a biopharmaceutical company, has launched RHO Phyto Micro Drop 100, a new THC-free, ...

Avicanna Releases New CBD Formulation in Canada

Avicanna Inc (TSE:AVCN) has released an update. Avicanna Inc. has reported a significant 314% increase in annual revenue for 2023, hitting $16.8 mi...

Avicanna Inc. Celebrates Soaring 2023 Profits

Avicanna Inc. (AVCNF) Q4 2023 Earnings Call Transcript

Avicanna reports FY results

Avicanna Inc (TSE:AVCN) has released an update. Avicanna Inc. has successfully completed an observational study on a cannabigerol (CBG) transdermal...